These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 7793876)
61. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. Chen HY; Yuan M; Livermore DM J Med Microbiol; 1995 Oct; 43(4):300-9. PubMed ID: 7562993 [TBL] [Abstract][Full Text] [Related]
62. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
63. Evaluation of high-level carbapenem resistance in atypical Serratia marcescens by a comparison with its revertants. Marumo K; Nagaki T; Nakamura Y J Antimicrob Chemother; 1996 Jul; 38(1):47-58. PubMed ID: 8858456 [TBL] [Abstract][Full Text] [Related]
64. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa. Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003 [TBL] [Abstract][Full Text] [Related]
65. Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. Fournier D; Richardot C; Müller E; Robert-Nicoud M; Llanes C; Plésiat P; Jeannot K J Antimicrob Chemother; 2013 Aug; 68(8):1772-80. PubMed ID: 23587654 [TBL] [Abstract][Full Text] [Related]
66. Roles of porin and beta-lactamase in beta-lactam resistance of Pseudomonas aeruginosa. Hancock RE; Woodruff WA Rev Infect Dis; 1988; 10(4):770-5. PubMed ID: 2460909 [TBL] [Abstract][Full Text] [Related]
67. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544 [TBL] [Abstract][Full Text] [Related]
68. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases]. Martínez-Beltrán J; Calderón C; Sierra MP; Alvarez M; Cantón R Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065 [TBL] [Abstract][Full Text] [Related]
69. Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta-lactamase in Pseudomonas aeruginosa. Mugnier P; Podglajen I; Goldstein FW; Collatz E Microbiology (Reading); 1998 Apr; 144 ( Pt 4)():1021-1031. PubMed ID: 9579076 [TBL] [Abstract][Full Text] [Related]
70. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412 [TBL] [Abstract][Full Text] [Related]
71. Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion. Gotoh N; Nishino T J Antimicrob Chemother; 1990 Feb; 25(2):191-8. PubMed ID: 2109748 [TBL] [Abstract][Full Text] [Related]
72. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa]. Yi MY; Wang PY; Huang HJ; Liu YC Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571 [TBL] [Abstract][Full Text] [Related]
73. Comparison of imipenem and meropenem antibiotics for the MALDI-TOF MS detection of carbapenemase activity. Rotova V; Papagiannitsis CC; Skalova A; Chudejova K; Hrabak J J Microbiol Methods; 2017 Jun; 137():30-33. PubMed ID: 28390706 [TBL] [Abstract][Full Text] [Related]
76. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064 [TBL] [Abstract][Full Text] [Related]
77. Distribution of carbapenem resistance mechanisms in clinical isolates of XDR Pseudomonas aeruginosa. De Rosa A; Mutters NT; Mastroianni CM; Kaiser SJ; Günther F Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1547-1552. PubMed ID: 31152264 [TBL] [Abstract][Full Text] [Related]
78. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan. Sanbongi Y; Shimizu A; Suzuki T; Nagaso H; Ida T; Maebashi K; Gotoh N Microbiol Immunol; 2009 Jul; 53(7):361-7. PubMed ID: 19563394 [TBL] [Abstract][Full Text] [Related]
79. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999 [TBL] [Abstract][Full Text] [Related]
80. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units. Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]